Trials
Search / Trial NCT06416930

Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma

Launched by CANCER INSTITUTE AND HOSPITAL, CHINESE ACADEMY OF MEDICAL SCIENCES · May 12, 2024

Trial Information

Current as of February 19, 2025

Not yet recruiting

Keywords

Cadonilimab Pleural Mesothelioma Bispecific Antibody

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Histologically confirmed advanced or metastatic pleural mesothelioma;
  • 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
  • 3. Participants must have previously failed to receive platinum-containing chemotherapy with or without bevacizumab, and have received at most two-line systemic therapy.
  • 4. Measurable disease as per mRECIST v1.1 for assessment of response in malignant pleural mesothelioma.
  • 5. Adequate haematological, renal and liver function.
  • Exclusion Criteria:
  • 1. Primary mesothelioma of peritoneum, pericardium and testes
  • 2. Active, untreated central nervous system (CNS) metastasis.
  • 3. Use of Chinese herbal medicine or immunomodulatory agents with anti-tumor indications within 14 days prior to the first dose of study treatment.
  • 4. Known active autoimmune diseases.
  • 5. Presence of other uncontrolled serious medical conditions.

About Cancer Institute And Hospital, Chinese Academy Of Medical Sciences

The Cancer Institute and Hospital of the Chinese Academy of Medical Sciences is a leading research and treatment center dedicated to advancing cancer care through innovative clinical trials and comprehensive patient services. As a prominent institution in oncology, it focuses on integrating cutting-edge research with clinical practice, fostering collaborations that enhance the understanding and treatment of various cancer types. The institute is committed to improving patient outcomes by exploring novel therapies, optimizing treatment protocols, and contributing to the global fight against cancer through rigorous scientific investigation and evidence-based practices.

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0